{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T11:36:26Z","timestamp":1781177786763,"version":"3.54.1"},"reference-count":22,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,6,12]],"date-time":"2020-06-12T00:00:00Z","timestamp":1591920000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000871","name":"Mayo Clinic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["mcpiqojournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Mayo Clinic Proceedings: Innovations, Quality & Outcomes"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.mayocpiqo.2020.06.002","type":"journal-article","created":{"date-parts":[[2020,8,19]],"date-time":"2020-08-19T11:48:30Z","timestamp":1597837710000},"page":"542-549","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Retrospective Analysis of Gabapentin for Alcohol Withdrawal in the Hospital Setting: The Mayo Clinic Experience"],"prefix":"10.1016","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2035-9614","authenticated-orcid":false,"given":"Ruth E.","family":"Bates","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3836-9375","authenticated-orcid":false,"given":"Jonathan G.","family":"Leung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0103-2090","authenticated-orcid":false,"suffix":"III","given":"Robert J.","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen M.","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kemuel L.","family":"Philbrick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Kung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3-4","key":"10.1016\/j.mayocpiqo.2020.06.002_bib1","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1080\/19371918.2013.758987","article-title":"The impact of alcohol on society: a brief overview","volume":"28","author":"Moss","year":"2013","journal-title":"Soc Work Public Health"},{"issue":"3","key":"10.1016\/j.mayocpiqo.2020.06.002_bib2","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1176\/appi.psy.45.3.256","article-title":"False positives on the clinical institute withdrawal assessment for alcohol-revised: is this scale appropriate for use in the medically ill?","volume":"45","author":"Bostwick","year":"2004","journal-title":"Psychosomatics"},{"issue":"8","key":"10.1016\/j.mayocpiqo.2020.06.002_bib3","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1177\/1060028015585849","article-title":"The role of gabapentin in the management of alcohol withdrawal and dependence","volume":"49","author":"Leung","year":"2015","journal-title":"Ann Pharmacother"},{"issue":"7","key":"10.1016\/j.mayocpiqo.2020.06.002_bib4","doi-asserted-by":"crossref","first-page":"695","DOI":"10.4065\/76.7.695","article-title":"Symptom-triggered therapy for alcohol withdrawal syndrome in medical inpatients","volume":"76","author":"Jaeger","year":"2001","journal-title":"Mayo Clin Proc"},{"issue":"7","key":"10.1016\/j.mayocpiqo.2020.06.002_bib5","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1001\/jama.1994.03520070039035","article-title":"Individualized treatment for alcohol withdrawal. A randomized double-blind controlled trial","volume":"272","author":"Saitz","year":"1994","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.mayocpiqo.2020.06.002_bib6","first-page":"40","article-title":"Gabapentin use in acute alcohol withdrawal management","volume":"35","author":"Wilming","year":"2018","journal-title":"Fed Pract"},{"issue":"1","key":"10.1016\/j.mayocpiqo.2020.06.002_bib7","first-page":"24","article-title":"Self-reported sleep, sleepiness, and repeated alcohol withdrawals: a randomized, double blind, controlled comparison of lorazepam vs gabapentin","volume":"3","author":"Malcolm","year":"2007","journal-title":"J\u00a0Clin Sleep Med"},{"issue":"2","key":"10.1016\/j.mayocpiqo.2020.06.002_bib8","first-page":"153","article-title":"Carbamazepine versus oxazepam in the treatment of alcohol withdrawal: a double-blind study","volume":"27","author":"Stuppaeck","year":"1992","journal-title":"Alcohol Alcohol"},{"issue":"9","key":"10.1016\/j.mayocpiqo.2020.06.002_bib9","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1111\/add.14655","article-title":"A\u00a0meta-analysis of the efficacy of gabapentin for treating alcohol use disorder","volume":"114","author":"Kranzler","year":"2019","journal-title":"Addiction"},{"issue":"10","key":"10.1016\/j.mayocpiqo.2020.06.002_bib10","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1016\/S0028-3908(97)00118-4","article-title":"The novel anticonvulsant, gabapentin, protects against both convulsant and anxiogenic aspects of the ethanol withdrawal syndrome","volume":"36","author":"Watson","year":"1997","journal-title":"Neuropharmacology"},{"issue":"8","key":"10.1016\/j.mayocpiqo.2020.06.002_bib11","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1001\/jama.2017.21547","article-title":"Gabapentin for chronic neuropathic pain","volume":"319","author":"Moore","year":"2018","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.mayocpiqo.2020.06.002_bib12","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1046\/j.1440-1819.2003.01161.x","article-title":"Open pilot study of gabapentin versus trazodone to treat insomnia in alcoholic outpatients","volume":"57","author":"Karam-Hage","year":"2003","journal-title":"Psychiatry Clin Neurosci"},{"issue":"12","key":"10.1016\/j.mayocpiqo.2020.06.002_bib13","doi-asserted-by":"crossref","first-page":"815","DOI":"10.3949\/ccjm.86a.18128","article-title":"Gabapentin for alcohol use disorder: a good option, or cause for concern?","volume":"86","author":"Modesto-Lowe","year":"2019","journal-title":"Cleve Clin J Med"},{"issue":"1","key":"10.1016\/j.mayocpiqo.2020.06.002_bib14","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/acer.13917","article-title":"Gabapentin enacarbil extended-release for alcohol use disorder: a randomized, double-blind, placebo-controlled, multisite trial assessing efficacy and safety","volume":"43","author":"Falk","year":"2019","journal-title":"Alcohol Clin Exp Res"},{"issue":"9","key":"10.1016\/j.mayocpiqo.2020.06.002_bib15","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1002\/phar.2309","article-title":"High-dose gabapentin for the treatment of severe alcohol withdrawal syndrome: a retrospective cohort analysis","volume":"39","author":"Levine","year":"2019","journal-title":"Pharmacotherapy"},{"issue":"1","key":"10.1016\/j.mayocpiqo.2020.06.002_bib16","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1080\/00952990.2019.1634085","article-title":"Fixed-dose gabapentin augmentation in the treatment of alcohol withdrawal syndrome: a retrospective, open-label study","volume":"46","author":"Andaluz","year":"2020","journal-title":"Am J Drug Alcohol Abuse"},{"issue":"1","key":"10.1016\/j.mayocpiqo.2020.06.002_bib17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.9740\/mhc.2019.01.001","article-title":"Alcohol withdrawal-related outcomes associated with gabapentin use in an inpatient psychiatric facility","volume":"9","author":"Nichols","year":"2019","journal-title":"Ment Health Clin"},{"issue":"1","key":"10.1016\/j.mayocpiqo.2020.06.002_bib18","doi-asserted-by":"crossref","first-page":"17","DOI":"10.64719\/pb.4587","article-title":"Impact of gabapentin adjunct use with benzodiazepines for the treatment of alcohol withdrawal in a psychiatric hospital","volume":"49","author":"Vadiei","year":"2019","journal-title":"Psychopharmacol Bull"},{"issue":"5","key":"10.1016\/j.mayocpiqo.2020.06.002_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1001\/jamainternmed.2020.0249","article-title":"Efficacy of gabapentin for the treatment of alcohol use disorder in patients with alcohol withdrawal symptoms: a randomized clinical trial","volume":"180","author":"Anton","year":"2020","journal-title":"JAMA Intern Med"},{"issue":"9","key":"10.1016\/j.mayocpiqo.2020.06.002_bib20","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1111\/j.1530-0277.2009.00986.x","article-title":"A\u00a0double-blind trial of gabapentin versus lorazepam in the treatment of alcohol withdrawal","volume":"33","author":"Myrick","year":"2009","journal-title":"Alcohol Clin Exp Res"},{"issue":"5","key":"10.1016\/j.mayocpiqo.2020.06.002_bib21","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.psym.2018.03.002","article-title":"Use of a gabapentin protocol for the management of alcohol withdrawal: a preliminary experience expanding from the consultation-liaison psychiatry service","volume":"59","author":"Leung","year":"2018","journal-title":"Psychosomatics"},{"issue":"4","key":"10.1016\/j.mayocpiqo.2020.06.002_bib22","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1080\/00952990.2019.1602136","article-title":"Retrospective analysis of a gabapentin high dose taper compared to lorazepam in acute inpatient alcohol withdrawal","volume":"45","author":"Morrison","year":"2019","journal-title":"Am J Drug Alcohol Abuse"}],"container-title":["Mayo Clinic Proceedings: Innovations, Quality & Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2542454820301041?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2542454820301041?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T14:09:35Z","timestamp":1762870175000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2542454820301041"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":22,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["S2542454820301041"],"URL":"https:\/\/doi.org\/10.1016\/j.mayocpiqo.2020.06.002","relation":{},"ISSN":["2542-4548"],"issn-type":[{"value":"2542-4548","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Retrospective Analysis of Gabapentin for Alcohol Withdrawal in the Hospital Setting: The Mayo Clinic Experience","name":"articletitle","label":"Article Title"},{"value":"Mayo Clinic Proceedings: Innovations, Quality & Outcomes","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mayocpiqo.2020.06.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Inc on behalf of Mayo Foundation for Medical Education and Research.","name":"copyright","label":"Copyright"}]}}